The FDA just added a NAION warning to every GLP-1 label, and the headlines are a lot scarier than the data.
Spencer and Karl recorded this one fast because the questions started pouring in, from patients and from colleagues across endocrinology and obesity medicine. If you’ve seen the news and wondered whether you should stop your medication, this is the episode.
They break down what NAION actually is, why the absolute risk is so different from the relative risk you’re reading about, and what the number needed to harm really works out to. They get into the likely mechanism, why sleep apnea and blood pressure matter here, and one detail in how the FDA reported its own data that’s worth paying attention to.
They also cover what the ophthalmology societies are recommending, including whether you need an eye exam before starting one of these medications. The answer may surprise you given what’s circulating online.
Bottom line: this is not a black box warning, not a recall, and not a reason to quit your medication on your own. But there’s one symptom that should send you to an ophthalmologist immediately, no matter what you’re taking.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.